pretickt

Boston Scientific Corporation (BSX)

Healthcare · end-of-day data as of Oct 16, 2026

Boston Scientific Corporation
BSX · $64.33B
$44.39+0.3%last 60 sessions · close Oct 16, 2026
$41.58$104.9852 weeks
Buy · 32 analystsPT $66.64 +50.1%
  • P/E vs own-50.4%
  • P/E vs sector-35.9%
  • Target upside+50.1%
  • Off 52w high-57.7%
  • Insiders$9.49M
  • FCF yield+5.6%
  • Earnings in12d
  • Trendbearish
  • Sector▲ +16.0%
  • RSI53
  • MA20×50↑ in ~33d
  • Volume0.7x
  • Support-3.5%
  • Resistance+1.6%

The average 12-month analyst price target for BSX is $66.64, 50.1% above the last close of $44.39 on Oct 16, 2026; targets range from $48.00 to $128.17. Rating consensus: Buy.

Snapshot

  • P/E18.0x
  • P/E vs sector-35.9%
  • P/E vs own-50.4%
  • Target upside+50.1%
  • ConsensusBuy
  • Market cap$64.33B
  • FCF yield+5.6%
  • Insiders$9.49M
  • Earnings in12d
  • News

Why it moved

Boston Scientific Corporation (BSX) rose 0.6% on Oct 16, 2026.

The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to BSX.

Market (SPY)-1.1%
Healthcare sector+0.4%
BSX specific+1.3%

1 story on the day (30-day average 0.7).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$45.70$64.09$82.47$101Oct 25Jan 26Apr 26Jul 26Oct 26EEAEAAEAAE

Last close $44.39 · -54.6% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

  • Trendbearish
  • Sector▲ +16.0%
  • MAs20▲ 50▼ 100▼ 200▼
  • Above MAs1 of 4 above
  • MA20×50↑ in ~33d
  • RSI53
  • Support-3.5%
  • Resistance+1.6%
  • Off 52w high-57.7%
  • Off ATH-59.0%
  • 52w range$44.39
  • Bollingerupper half
  • MACD0.31
  • ATR+2.8%
  • Volume0.7x

Analyst price targets

Low$48.00
Average$66.64
Median$59.95
High$128.17
Upside+50.1%

23 firms with a target in the last 12 months · last close $44.39 · as of Oct 16, 2026

⇔⇕$36.78$63.17$89.55$116$142Oct 25Mar 26Aug 26Jan 27Jun 27+189%+151%+91%+46%+21%+69%+29%+23%+8%
— actual price● bullish target● bearish targethover a dot to see the analysts behind it · wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets

Strong buy 8 · Buy 18 · Hold 6 · Sell 0 · Strong sell 0

Revenue and free cash flow

Q2 FY2026: Revenue +7.5% year over year, free cash flow 23.5% of revenue, operating margin 21.6%.

RevenueFree cash flow
Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026
Q2 FY2026Jun 30, 2026$5.44B0.61$1.28B70.7%21.6%16.7%
Q1 FY2026Mar 31, 2026$5.2B0.90$171M69.4%20.6%25.7%
Q4 FY2025Dec 31, 2025$5.29B0.45$1.01B74.5%22.8%12.6%
Q3 FY2025Sep 30, 2025$5.07B0.50$1.16B69.9%20.7%14.9%
Q2 FY2025Jun 30, 2025$5.06B0.53$1.1B67.7%16.2%15.7%
Q1 FY2025Mar 31, 2025$4.66B0.45$354M63.3%19.2%14.5%
Q4 FY2024Dec 31, 2024$4.56B0.38$1.16B58.6%12.9%12.4%
Q3 FY2024Sep 30, 2024$4.21B0.32$698M62.9%16.0%11.1%

Peers

20D
1ABTAbbott Laboratories$104.89+0.2%-17.7%+16.6%33.7$181B
2MDTMedtronic Plc$94.75-0.7%-7.1%+4.0%23.3$121B
3SYKStryker Corporation$294.66+0.5%-23.3%+23.9%30.5$113B
4BSXBoston Scientific Corporation$44.39+0.6%-57.7%+50.1%18.0$64.33B
5EWEdwards Lifesciences Corporation$86.60-1.7%-9.0%+15.2%49.8$49.9B
6DXCMDexCom, Inc.$86.04-1.9%-6.8%+12.7%34.0$32.47B
7GEHCGE HealthCare Technologies Inc.$69.57-1.1%-21.0%+20.2%20.2$31.42B
8ZBHZimmer Biomet Holdings, Inc.$94.98+0.6%-7.7%+9.0%23.1$18.12B

Data as of Oct 16, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.